Xiehe Group To Set Up Base In Shenzhen
This article was originally published in PharmAsia News
China's leading biopharmaceutical company, Shenyang Xiehe Group, has announced it will set up a wholly-owned subsidiary in Shenzhen High-Tech Industrial Park; it will also site its future R&D and international base in the city. Xiehe Group, a multinational conglomerate with 33 subsidiaries worldwide, integrates R&D, production and trading for health care items, biopharmaceuticals and other high-tech products. Its product value is expected to reach RMB 4 billion by 2010. The latest move is an important step in Xiehe Group's rapid growth as it will tap on Shenzhen's advantages in location and manufacturing to reap its R&D translational output as well as expand sales. The company has already established R&D centers in the U.S., Hong Kong and Shenyang. (Click here for more - Chinese Language)
You may also be interested in...
ODAC's 17-18 June discussion of pediatric development plans for four investigational oncology agents will serve as a trial run of the technology platform and logistics for any future application-specific virtual advisory committee meeting, but without the stress associated with a pending application and a user fee deadline.
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.